Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3

PLoS One. 2018 Feb 16;13(2):e0192452. doi: 10.1371/journal.pone.0192452. eCollection 2018.

Abstract

Several probiotic-marketed formulations available for the consumers contain live lactic acid bacteria and/or bifidobacteria. The multispecies product commercialized as VSL#3 has been used for treating various gastro-intestinal disorders. However, like many other products, the bacterial strains present in VSL#3 have only been characterized to a limited extent and their efficacy as well as their predicted mode of action remain unclear, preventing further applications or comparative studies. In this work, the genomes of all eight bacterial strains present in VSL#3 were sequenced and characterized, to advance insights into the possible mode of action of this product and also to serve as a basis for future work and trials. Phylogenetic and genomic data analysis allowed us to identify the 7 species present in the VSL#3 product as specified by the manufacturer. The 8 strains present belong to the species Streptococcus thermophilus, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus helveticus, Bifidobacterium breve and B. animalis subsp. lactis (two distinct strains). Comparative genomics revealed that the draft genomes of the S. thermophilus and L. helveticus strains were predicted to encode most of the defence systems such as restriction modification and CRISPR-Cas systems. Genes associated with a variety of potential probiotic functions were also identified. Thus, in the three Bifidobacterium spp., gene clusters were predicted to encode tight adherence pili, known to promote bacteria-host interaction and intestinal barrier integrity, and to impact host cell development. Various repertoires of putative signalling proteins were predicted to be encoded by the genomes of the Lactobacillus spp., i.e. surface layer proteins, LPXTG-containing proteins, or sortase-dependent pili that may interact with the intestinal mucosa and dendritic cells. Taken altogether, the individual genomic characterization of the strains present in the VSL#3 product confirmed the product specifications, determined its coding capacity as well as identified potential probiotic functions.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Adhesion
  • Bifidobacterium / classification
  • Bifidobacterium / genetics
  • CRISPR-Cas Systems
  • Genome, Bacterial*
  • Genomics
  • Humans
  • Intestinal Mucosa / microbiology
  • Lacticaseibacillus paracasei / classification
  • Lacticaseibacillus paracasei / genetics
  • Lactobacillus / classification
  • Lactobacillus / genetics
  • Lactobacillus acidophilus / classification
  • Lactobacillus acidophilus / genetics
  • Lactobacillus plantarum / classification
  • Lactobacillus plantarum / genetics
  • Microbial Sensitivity Tests
  • Phylogeny
  • Probiotics / classification*

Grants and funding

The present study was partly supported by Actial Farmaceutical SRL (Rome, Italy), by the Spinoza Award (https://www.nwo.nl/en/research-and-results/programmes/spinoza+prize), by the SIAM Gravitation Grant 024.002.002 of the Netherlands Organization for Scientific Research (http://www.ru.nl/english/research/prizes-achievements/gravitation/) and by the University of Helsinki. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. In addition, we have included all information about the funders of this work and the employment of two of the co-authors in a small company NIZO. The funder provided support in the form of salaries for authors [MW and RTE], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.